Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tilsotolimod + ipilimumab in refractory melanoma
NCT03445533Phase 3Terminated
- Sponsor
- Aceragen, Inc.
- Start
- May 2018
- Primary completion
- Jun 2021
- Modality
- Antisense DNA, Small Interfering RNA (siRNA), MicroRNA (miRNA)
- Countries
- 11
01
Overview
A Phase 3 trial of tilsotolimod in melanoma, sponsored by Aceragen, Inc.. Started May 2018; status: terminated.
02
Drugs
tilsotolimod
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT03445533.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03445533.